The IVD development of rift valley fever (RVF) is a critical component of disease control and surveillance. Within our company, we are dedicated to pioneering cutting-edge antigen, antibodie, RNA detection reagents/kits, and accompanying diagnostic devices to overcome the obstacles faced in RVF diagnosis. Serving as your trusted collaborator in RVF diagnostic research, we deliver efficient and all-encompassing solutions tailored to satisfy your scientific research needs.
Overview of Rift Valley Fever
Rift valley fever (RVF) is a viral zoonosis that primarily affects animals but can also infect humans. RVF is usually transmitted through contact with infected animal tissues (such as blood or organs) or mosquito bites. Severe cases of RVF can present as eye disease, meningoencephalitis, or hemorrhagic fever. RVF primarily affects regions of Africa, and its prevalence highlights the importance of robust diagnostic tools and effective disease management strategies.
Fig. 1 Distribution of rift valley fever (RVF). (Wright, Daniel, et al., 2020)
Diagnostic Biomarkers for Rift Valley Fever
Identification of specific diagnostic biomarkers plays a vital role in the accurate and timely detection of rift valley fever (RVF), which can help develop effective disease management and control strategies. These biomarkers may include specific proteins, nucleic acids, or other molecular entities that indicate RVF infection or disease progression.
Antigens
Antigen detection tests are particularly valuable in the early stages of RVF infection, when viral RNA levels may be low. Rapid and accurate identification of viral antigens can aid in timely diagnosis and intervention.
Antibodies
Detection of specific antibodies, particularly IgM and IgG, are important biomarkers for assessing past or current infection. ELISA and rapid diagnostic tests (RDT) are commonly used to detect RVF-specific antibodies in serum samples.
Viral RNA
Detection of RVF virus RNA is a direct and sensitive method to confirm active infection. Viral RNA is often detected during the acute phase of the disease, making it a valuable biomarker for early diagnosis and monitoring.
IVD Development for Rift Valley Fever
In the battle against rift valley fever (RVF), in vitro diagnostic (IVD) kits are essential tools, pivotal in the early detection, precise diagnosis, and efficient management and containment of outbreaks. Developing accurate and dependable IVD kits can expedite the identification of RVF cases, enabling prompt and suitable implementation of therapies and control measures.
| Kits |
Description |
Detection Methods |
| Antigen Detection Kit |
Detection of RVF virus antigen in samples. |
ELISA, IFA |
| Antibody Detection Kit |
Detection of RVF-specific IgM and IgG antibodies in serum samples. |
ELISA |
| RNA Detection Kit |
Detection of RVF virus RNA in blood samples. |
PCR |
Our Services
To address the current void in in vitro diagnostics (IVD) for rift valley fever (RVF), our firm is dedicated to the creation of a comprehensive array of antigen, antibody, and RNA detection kits tailored for the precise identification of this viral infectious disease. Furthermore, we actively engage in the development of state-of-the-art IVD equipment to enhance detection efficiency and streamline the automated diagnostic process.
Our point-of-care testing (POCT) is meticulously crafted to deliver swift on-site results, rendering them invaluable diagnostic tools in environments with limited resources. Through the identification of disease-associated biomarkers and genetic factors, our companion diagnostics assume a crucial role in guiding personalized therapy and improving therapeutic efficacy.
If you are interested in our services, please don't hesitate to reach out to us for further information and pricing details on the services we offer.
Reference
- Wright, Daniel, et al. "Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein." Iscience 23.11 (2020).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
